JP2010536876A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010536876A5 JP2010536876A5 JP2010522030A JP2010522030A JP2010536876A5 JP 2010536876 A5 JP2010536876 A5 JP 2010536876A5 JP 2010522030 A JP2010522030 A JP 2010522030A JP 2010522030 A JP2010522030 A JP 2010522030A JP 2010536876 A5 JP2010536876 A5 JP 2010536876A5
- Authority
- JP
- Japan
- Prior art keywords
- dihydro
- pyrrolo
- compound
- composition
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 51
- -1 —CH 2 -aryl Chemical group 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 8
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 8
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 8
- 229940127089 cytotoxic agent Drugs 0.000 claims description 8
- 229960001433 erlotinib Drugs 0.000 claims description 8
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 230000002062 proliferating effect Effects 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 208000015114 central nervous system disease Diseases 0.000 claims description 5
- 239000002207 metabolite Substances 0.000 claims description 5
- 229940002612 prodrug Drugs 0.000 claims description 5
- 239000000651 prodrug Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 4
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 4
- 101100002068 Bacillus subtilis (strain 168) araR gene Proteins 0.000 claims description 4
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 4
- 108010092160 Dactinomycin Proteins 0.000 claims description 4
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 4
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 4
- 108010069236 Goserelin Proteins 0.000 claims description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 4
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 4
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 4
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 claims description 4
- 229960001220 amsacrine Drugs 0.000 claims description 4
- 229960002932 anastrozole Drugs 0.000 claims description 4
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 4
- 101150044616 araC gene Proteins 0.000 claims description 4
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 229960000397 bevacizumab Drugs 0.000 claims description 4
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 4
- 229940127093 camptothecin Drugs 0.000 claims description 4
- 229960004562 carboplatin Drugs 0.000 claims description 4
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- 229960005395 cetuximab Drugs 0.000 claims description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- 229960004397 cyclophosphamide Drugs 0.000 claims description 4
- 229960000640 dactinomycin Drugs 0.000 claims description 4
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 4
- 229960003668 docetaxel Drugs 0.000 claims description 4
- 229960004679 doxorubicin Drugs 0.000 claims description 4
- 229960001904 epirubicin Drugs 0.000 claims description 4
- 229930013356 epothilone Natural products 0.000 claims description 4
- 150000003883 epothilone derivatives Chemical class 0.000 claims description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 4
- 229960005420 etoposide Drugs 0.000 claims description 4
- 229960000255 exemestane Drugs 0.000 claims description 4
- 229960002949 fluorouracil Drugs 0.000 claims description 4
- 229960002584 gefitinib Drugs 0.000 claims description 4
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 4
- 229960005277 gemcitabine Drugs 0.000 claims description 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 4
- 229960002913 goserelin Drugs 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 claims description 4
- 229960003881 letrozole Drugs 0.000 claims description 4
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 4
- 229960004844 lovastatin Drugs 0.000 claims description 4
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 4
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 4
- 229960000485 methotrexate Drugs 0.000 claims description 4
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 4
- 229960001156 mitoxantrone Drugs 0.000 claims description 4
- 229940086322 navelbine Drugs 0.000 claims description 4
- 229950006344 nocodazole Drugs 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 229960004622 raloxifene Drugs 0.000 claims description 4
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 4
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 229960001603 tamoxifen Drugs 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 4
- 229960001278 teniposide Drugs 0.000 claims description 4
- 229960003048 vinblastine Drugs 0.000 claims description 4
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 4
- 229960004528 vincristine Drugs 0.000 claims description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 4
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 3
- CYZDKOSGLHTOBO-UHFFFAOYSA-N 3-[1-(5,6-dihydro-4h-pyrrolo[3,2,1-ij]quinoline-1-carbonyl)-piperidin-4-yl]-n-hydroxy-propionamide Chemical compound C1CC(CCC(=O)NO)CCN1C(=O)C1=CN2C3=C1C=CC=C3CCC2 CYZDKOSGLHTOBO-UHFFFAOYSA-N 0.000 claims description 2
- JKIZKMYMKFMYEN-UHFFFAOYSA-N 4-[1-(5,6-dihydro-4h-pyrrolo[3,2,1-ij]quinolin-1-ylcarbonyl)piperidin-4-yl]butan-2-one Chemical compound C1CC(CCC(=O)C)CCN1C(=O)C1=CN2C3=C1C=CC=C3CCC2 JKIZKMYMKFMYEN-UHFFFAOYSA-N 0.000 claims description 2
- WAFYQXMJDRSPSG-UHFFFAOYSA-N 4-[[2-(1-azatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-3-yl)-2-oxoacetyl]amino]-N-hydroxybutanamide Chemical compound C1CCC2=CC=CC3=C2N1C=C3C(=O)C(=O)NCCCC(=O)NO WAFYQXMJDRSPSG-UHFFFAOYSA-N 0.000 claims description 2
- CYMDMEIWWITWNA-UHFFFAOYSA-N 4-[[2-(1-azatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-3-yl)-2-oxoacetyl]amino]-N-hydroxypentanamide Chemical compound C1CCC2=CC=CC3=C2N1C=C3C(=O)C(=O)NC(CCC(=O)NO)C CYMDMEIWWITWNA-UHFFFAOYSA-N 0.000 claims description 2
- ONEUCCISOJRBMM-UHFFFAOYSA-N 5,6-dihydro-4h-pyrrolo[3,2,1-ij]quinoline-1-carboxylic acid (5-hydroxy carbamoyl-pentyl)-amide Chemical compound C1CCC2=CC=CC3=C2N1C=C3C(=O)NCCCCCC(=O)NO ONEUCCISOJRBMM-UHFFFAOYSA-N 0.000 claims description 2
- MVVPTNAUYQYMKV-UHFFFAOYSA-N 6-(1-azatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-3-ylcarbamoylamino)-N-hydroxyhexanamide Chemical compound C1CCC2=CC=CC3=C2N1C=C3NC(=O)NCCCCCC(=O)NO MVVPTNAUYQYMKV-UHFFFAOYSA-N 0.000 claims description 2
- YNHWIAIXSNSJRH-UHFFFAOYSA-N 6-[[2-(1-azatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraen-3-yl)-2-oxoacetyl]amino]-N-hydroxyhexanamide Chemical compound C1CCC2=CC=CC3=C2N1C=C3C(=O)C(=O)NCCCCCC(=O)NO YNHWIAIXSNSJRH-UHFFFAOYSA-N 0.000 claims description 2
- FTQMHSQPUYFMNX-UHFFFAOYSA-N 7-{[5,6-dihydro-4h-pyrrolo[3,2,1-ij]quinolin-1-yl(oxo)acetyl]amino}-n-hydroxyheptanamide Chemical compound C1CCC2=CC=CC3=C2N1C=C3C(=O)C(=O)NCCCCCCC(=O)NO FTQMHSQPUYFMNX-UHFFFAOYSA-N 0.000 claims description 2
- 206010000830 Acute leukaemia Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000036626 Mental retardation Diseases 0.000 claims description 2
- 208000026072 Motor neurone disease Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- LZZMIITWPJDCBZ-UHFFFAOYSA-N N-[5-(hydroxyamino)-5-oxopentyl]-1-azatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraene-3-carboxamide Chemical compound C1CCC2=CC=CC3=C2N1C=C3C(=O)NCCCCC(=O)NO LZZMIITWPJDCBZ-UHFFFAOYSA-N 0.000 claims description 2
- GCRJCJYORXVXKU-UHFFFAOYSA-N N-[7-(2-amino-4,5-dichloroanilino)-7-oxoheptyl]-1-azatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraene-3-carboxamide Chemical compound NC1=CC(Cl)=C(Cl)C=C1NC(=O)CCCCCCNC(=O)C1=CN2C3=C1C=CC=C3CCC2 GCRJCJYORXVXKU-UHFFFAOYSA-N 0.000 claims description 2
- YXVYWXJQRXAWQI-UHFFFAOYSA-N N-[8-(hydroxyamino)-8-oxooctyl]-1-azatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraene-3-carboxamide Chemical compound C1CCC2=CC=CC3=C2N1C=C3C(=O)NCCCCCCCC(=O)NO YXVYWXJQRXAWQI-UHFFFAOYSA-N 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000006994 Precancerous Conditions Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000006289 Rett Syndrome Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 208000024207 chronic leukemia Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 208000029824 high grade glioma Diseases 0.000 claims description 2
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000011614 malignant glioma Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000037819 metastatic cancer Diseases 0.000 claims description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 208000005264 motor neuron disease Diseases 0.000 claims description 2
- WQFNMMAWEXUDIB-UHFFFAOYSA-N n-(6-oxoheptyl)-5,6-dihydro-4h-pyrrolo[3,2,1-ij]quinoline-1-carboxamide Chemical compound C1CCC2=CC=CC3=C2N1C=C3C(=O)NCCCCCC(=O)C WQFNMMAWEXUDIB-UHFFFAOYSA-N 0.000 claims description 2
- XFHLLPYFEXLXMN-UHFFFAOYSA-N n-[7-(hydroxyamino)-7-oxoheptyl]-5,6-dihydro-4h-pyrrolo[3,2,1-ij]quinoline-1-carboxamide Chemical compound C1CCC2=CC=CC3=C2N1C=C3C(=O)NCCCCCCC(=O)NO XFHLLPYFEXLXMN-UHFFFAOYSA-N 0.000 claims description 2
- MWNIBCCCJVALQB-UHFFFAOYSA-N n-[7-(hydroxyamino)-7-oxoheptyl]-6-(3-methoxyphenyl)imidazo[2,1-b][1,3]thiazole-2-carboxamide Chemical compound COC1=CC=CC(C=2N=C3SC(=CN3C=2)C(=O)NCCCCCCC(=O)NO)=C1 MWNIBCCCJVALQB-UHFFFAOYSA-N 0.000 claims description 2
- SESSWCGDZHNKHR-UHFFFAOYSA-N n-benzyl-n-[7-(hydroxyamino)-7-oxoheptyl]-5,6-dihydro-4h-pyrrolo[3,2,1-ij]quinoline-1-carboxamide Chemical compound C=1N(C=23)CCCC3=CC=CC=2C=1C(=O)N(CCCCCCC(=O)NO)CC1=CC=CC=C1 SESSWCGDZHNKHR-UHFFFAOYSA-N 0.000 claims description 2
- HQHOVGRLHAUNON-UHFFFAOYSA-N n-{4-[2-(hydroxyamino)-2-oxoethyl]phenyl}-5,6-dihydro-4h-pyrrolo[3,2,1-ij]quinoline-1-carboxamide Chemical compound C1=CC(CC(=O)NO)=CC=C1NC(=O)C1=CN2C3=C1C=CC=C3CCC2 HQHOVGRLHAUNON-UHFFFAOYSA-N 0.000 claims description 2
- CTBONNKEEAZCOP-UHFFFAOYSA-N n-{7-[(2-aminophenyl)amino]-7-oxoheptyl}-5,6-dihydro-4h-pyrrolo[3,2,1-ij]quinoline-1-carboxamide Chemical compound NC1=CC=CC=C1NC(=O)CCCCCCNC(=O)C1=CN2C3=C1C=CC=C3CCC2 CTBONNKEEAZCOP-UHFFFAOYSA-N 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- ZEXKKIXCRDTKBF-UHFFFAOYSA-N quinoline-2-carboxamide Chemical compound C1=CC=CC2=NC(C(=O)N)=CC=C21 ZEXKKIXCRDTKBF-UHFFFAOYSA-N 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 16
- 238000000034 method Methods 0.000 description 13
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96558407P | 2007-08-21 | 2007-08-21 | |
| PCT/US2008/073873 WO2009026446A2 (en) | 2007-08-21 | 2008-08-21 | Hdac inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010536876A JP2010536876A (ja) | 2010-12-02 |
| JP2010536876A5 true JP2010536876A5 (https=) | 2012-09-13 |
Family
ID=39828970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010522030A Withdrawn JP2010536876A (ja) | 2007-08-21 | 2008-08-21 | Ｈｄａｃインヒビター |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100261710A1 (https=) |
| EP (1) | EP2190845A2 (https=) |
| JP (1) | JP2010536876A (https=) |
| CN (1) | CN101835778A (https=) |
| CA (1) | CA2695452A1 (https=) |
| WO (1) | WO2009026446A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5688367B2 (ja) | 2008-08-29 | 2015-03-25 | トポターゲット・アクティーゼルスカブＴｏｐｏＴａｒｇｅｔ Ａ／Ｓ | 新規なウレアおよびチオウレア誘導体 |
| WO2011082266A2 (en) | 2009-12-30 | 2011-07-07 | Arqule, Inc. | Substituted heterocyclic compounds |
| US8546588B2 (en) | 2010-02-26 | 2013-10-01 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| WO2011106632A1 (en) * | 2010-02-26 | 2011-09-01 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| WO2013041407A1 (en) * | 2011-09-19 | 2013-03-28 | Cellzome Ag | Hydroxamic acids as hdac6 inhibitors |
| JP6272773B2 (ja) * | 2011-11-29 | 2018-01-31 | ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． | Ｈｄａｃ６阻害剤・抗腫瘍剤用複素環アミド化合物 |
| WO2013154870A1 (en) | 2012-04-10 | 2013-10-17 | Annji Pharmaceutical Co., Ltd. | Histone deacetylases (hdacs) inhibitors |
| US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| US9878986B2 (en) | 2013-04-29 | 2018-01-30 | Chong Kun Dang Pharmaceutical Corp. | Compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same |
| CN110621317B (zh) | 2017-05-16 | 2023-05-12 | 安基生技新药股份有限公司 | 组蛋白去乙酰化酶（hdacs）抑制剂 |
| CN113121527B (zh) * | 2019-12-31 | 2024-09-06 | 上海辉启生物医药科技有限公司 | 三环类化合物及其用途 |
| JP2023530788A (ja) | 2020-06-08 | 2023-07-19 | アンジー ファーマシューティカル カンパニー リミテッド | 選択的ｈｄａｃ６阻害剤として有用なキナゾリン誘導体 |
| CN119143740B (zh) * | 2024-08-15 | 2025-11-14 | 杭州科兴生物化工有限公司 | 一种苯并噻吩类衍生物及其制备方法与应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1335898B1 (en) * | 2000-09-29 | 2005-11-23 | TopoTarget UK Limited | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
| AR035417A1 (es) * | 2001-01-27 | 2004-05-26 | Hoffmann La Roche | Derivados triciclicos de lactama y sultama, procesos para su elaboracion, medicamentos que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos |
| EP1644323B1 (en) * | 2003-07-07 | 2015-03-18 | Georgetown University | Histone deacetylase inhibitors and methods of use thereof |
| ITFI20050041A1 (it) * | 2005-03-15 | 2006-09-16 | Menarini Internat Operations Luxembourg Sa | Idrossammati come inibitori dell'istone deacelitasi, loro preparazione e formulazioni farmaceutiche che li contengono |
-
2008
- 2008-08-21 US US12/671,351 patent/US20100261710A1/en not_active Abandoned
- 2008-08-21 EP EP08827808A patent/EP2190845A2/en not_active Withdrawn
- 2008-08-21 JP JP2010522030A patent/JP2010536876A/ja not_active Withdrawn
- 2008-08-21 CA CA2695452A patent/CA2695452A1/en not_active Abandoned
- 2008-08-21 WO PCT/US2008/073873 patent/WO2009026446A2/en not_active Ceased
- 2008-08-21 CN CN200880112378A patent/CN101835778A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010536876A5 (https=) | ||
| JP7169469B2 (ja) | Ｂｒａｆ関連疾患および障害を処置するために有用なキナゾリン－４－オン誘導体 | |
| CN114599361B (zh) | Prmt5抑制剂的药物组合物 | |
| TWI757722B (zh) | 以雜環化合物作為激酶抑制劑的治療用途 | |
| CN112204027A (zh) | Erk 抑制剂及其应用 | |
| JP2018534289A5 (https=) | ||
| JP2021525783A5 (https=) | ||
| JP5537035B2 (ja) | Ｃｄｋ阻害剤、および成長因子抗体または抗有糸分裂剤を含む組合せ | |
| EP2842956A1 (en) | PARP inhibitor compounds, compositions and methods of use | |
| JP7394768B2 (ja) | キナーゼ阻害剤としての環状イミノピリミジン誘導体 | |
| JP6862563B2 (ja) | ナフチリジン化合物、薬物組成物およびそれらの使用 | |
| JP7778745B2 (ja) | Ｒｈｏ関連コイルドコイル含有プロテインキナーゼの阻害剤 | |
| KR20100024932A (ko) | 비사이클로아닐린 유도체 | |
| JP2015523390A5 (https=) | ||
| JP2008156336A5 (https=) | ||
| JP2013056930A5 (https=) | ||
| EP3154957A1 (en) | Novel compounds as dual inhibitors of histone methyltransferases and dna methyltransferases | |
| RU2012120288A (ru) | Новые производные нафтиридина и их применение в качестве ингибиторов киназы | |
| JP2010533699A5 (https=) | ||
| RU2008102381A (ru) | Ингибиторы тирозинкиназы | |
| PT2004653E (pt) | N- (aril ou heteroaril)-pirazo [1,5-a] pirimidinas substituídas na posição 3 como inibidoras de quinases | |
| JP2017513893A5 (https=) | ||
| CA2993809C (en) | Compounds and pharmaceutical composition associated with ubiquitination-proteasome system | |
| JPWO2020032105A5 (https=) | ||
| JP2018538260A5 (https=) |